California is still becoming a global center for innovation. It gets billions of dollars in venture capital each year. While the state is home to countless success stories, Series A funding remains a pivotal moment for any startup. It represents the leap from proof-of-concept to scaling operations, expanding teams, and tackling bigger markets.
This year has seen a particularly exciting mix of companies across technology, biotech, and fintech secure their Series A rounds, signaling confidence from investors and momentum for each team’s vision.
Here, we spotlight 10 California-based startups that have closed significant Series A rounds in 2025. Each has taken a bold step toward reshaping its industry, whether by pushing the boundaries of AI in drug discovery, reinventing enterprise software, or rethinking how we move through cities.
By arranging them from the smallest to the largest funding rounds, we can appreciate the breadth of innovation happening across different investment levels.
Millie – $12M
Millie, a healthtech startup headquartered in California, raised $12 million in Series A funding this February.
The company is dedicated to transforming maternal healthcare through a hybrid model that blends in-person clinics with a robust virtual care platform. This approach ensures that women receive continuous, personalized care during prenatal and postpartum stages, supported by an intuitive app and remote monitoring tools.
What sets Millie apart is its focus on both technology and human-centered service. The team has built a model that addresses gaps in traditional maternity care, ensuring that expectant and new mothers receive consistent, evidence-based guidance without losing the personal touch.
The $12 million round, backed by an all-female investor class, reflects growing awareness of the need for innovation in women’s health.
This capital infusion will allow Millie to expand its network of clinics and strengthen its digital offerings. As maternal health challenges persist across the United States, the company’s approach offers a replicable blueprint for improving outcomes and patient satisfaction.
Tailor – $22M
Tailor, a San Francisco-based enterprise software company, secured $22 million in Series A funding in June.
Tailor offers a headless ERP system called Omakase, designed to separate front-end modules from back-end infrastructure. This architecture allows companies to customize their workflows without being locked into rigid systems, a flexibility that resonates with businesses seeking agility.
In an era where AI is becoming deeply integrated into enterprise operations, Tailor’s platform stands out for its ability to connect with AI agents via API. This means that automation and advanced analytics can be layered seamlessly into day-to-day operations.
The company’s focus on modularity also enables faster adaptation to market changes and evolving customer demands.
With the new funding, Tailor plans to expand both its engineering capabilities and customer base. By targeting sectors that rely heavily on customizable ERP systems, the company is positioning itself to become a trusted backbone for digital transformation.
Rillet – $25M
Rillet, based in Palo Alto, is reimagining the ERP landscape for finance teams. The company raised $25 million in May, led by Sequoia Capital
Rillet’s platform leverages AI to handle core financial processes such as reconciliations, reporting, and compliance monitoring. This automation allows CFOs and finance teams to focus on strategic decisions rather than manual data processing.
The rise of AI-native platforms is reshaping how financial data is handled. Rillet’s system not only accelerates workflows but also improves accuracy by reducing human error. By embedding AI into the very fabric of ERP functions, the company delivers both speed and confidence in financial decision-making.
This Series A round will fuel further product development and market expansion. Given the competitive nature of enterprise software, Rillet’s blend of deep automation and user-centric design could place it ahead of older, more cumbersome finance solutions.
Conversion – $28M
Conversion, an AI-powered marketing automation startup founded by two UC Berkeley dropouts, closed a $28 million Series A round in July.
Based in California, the company is building a platform designed to help B2B businesses automate and personalize their marketing campaigns at scale. Its tools integrate with existing CRM and analytics systems, allowing companies to deliver targeted, data-driven outreach without overwhelming their marketing teams.
The strength of Conversion’s approach lies in its blend of AI-driven insights and seamless execution. The platform not only identifies the best prospects to engage but also crafts messaging that aligns with their needs and behavior.
This capability helps businesses shorten sales cycles, improve lead conversion rates, and maximize the impact of their marketing budgets.
With its Series A funding, Conversion plans to accelerate product development and expand its customer base across multiple industries. The company is also investing in AI research to enhance predictive capabilities, ensuring its clients can anticipate market shifts and act on emerging opportunities faster than their competitors.
Wispr Flow – $30M
Wispr Flow introduces a new dimension to productivity tools. The company raised $30 million in June for its AI-powered dictation app that lets users type by silently mouthing words.
This innovative speech-recognition technology converts unvoiced speech into text in real time, offering a discreet and efficient alternative to traditional typing.
Based in the San Francisco area, Wispr Flow’s platform appeals to professionals who need fast, accurate input methods without disrupting their surroundings. From busy offices to collaborative workspaces, the ability to “speak” without making a sound opens up new possibilities for digital communication.}
With Series A funding from Menlo Ventures and others, Wispr Flow is set to refine its algorithms, improve device integration, and broaden its market reach. The company’s vision aligns with a growing demand for tools that adapt to the user’s context rather than forcing the user to adapt to the tool.
Tahoe Therapeutics – $30M
Tahoe Therapeutics, located in South San Francisco, also closed a $30 million Series A round this August.
The biotech company is developing AI-powered “virtual cell” models capable of simulating drug interactions at the cellular level. This capability has the potential to dramatically speed up the process of identifying effective compounds for precision medicine.
The complexity of drug discovery often lies in predicting how molecules will behave in the human body. Tahoe’s virtual cell models address this challenge by providing detailed simulations that can reduce the need for lengthy and costly lab experiments.
The approach promises to accelerate timelines for developing treatments, especially in oncology and other high-need areas.
The Series A investment will enable Tahoe to expand its research capabilities, strengthen its AI modeling, and move promising candidates toward clinical trials. This work could ultimately shorten the path from scientific insight to patient treatment.
Vivodyne – $40M
Vivodyne is redefining preclinical drug testing with a $40 million Series A round led by Khosla Ventures.
The company grows lab-derived human tissues and uses robotics combined with AI to test how drugs interact with human biology. This creates a more predictive model for drug performance, potentially reducing the reliance on animal testing.
The advantage of Vivodyne’s approach lies in its ability to generate human-specific data earlier in the drug development process. By doing so, pharmaceutical companies can identify promising candidates and potential safety issues sooner, saving both time and resources.
With fresh funding, Vivodyne plans to expand its production capacity, enhance automation, and strengthen its AI models. This positions the company to become a vital partner for biotech and pharma companies seeking to innovate responsibly and efficiently.
Chai Discovery – $70M
Chai Discovery, based in San Francisco, secured $70 million in August to advance its AI models for antibody and therapeutic design. The company’s Chai-2 platform can generate novel drug candidates entirely in silico, accelerating what is traditionally a long and resource-intensive process
By applying frontier AI to molecular biology, Chai Discovery enables researchers to explore vast design spaces and optimize candidates before they enter the lab. This not only speeds up drug discovery but also improves the likelihood of finding effective treatments for complex diseases.
The new funding will allow Chai to refine its models, expand its dataset, and move more candidates into experimental validation. In a competitive biotech landscape, the ability to produce high-quality leads quickly could prove transformative.
Nexthop AI – $110M
Nexthop AI emerged from stealth in March with a $110 million Series A round. Based in Santa Clara, the company is developing networking hardware optimized for AI cloud data centers. This infrastructure is designed to handle the massive data flows required for training large AI models efficiently.
Current network architectures often struggle to keep pace with AI’s computational demands. Nexthop’s hardware aims to solve bottlenecks by delivering higher bandwidth, lower latency, and better scalability. These improvements could directly impact the performance and cost-efficiency of AI workloads.
The funding will support manufacturing, deployment, and continued R&D. As AI adoption accelerates across industries, the need for specialized infrastructure like Nexthop’s will only grow.
Also – $200M
Also, headquartered in Palo Alto, closed a remarkable $200 million Series A round led by Greenoaks Capital. Spun out of electric vehicle maker Rivian,
Also is focused on creating small form-factor electric vehicles designed for urban environments. This funding round valued the company at $1 billion, an impressive milestone for a Series A.
The company’s vision addresses a critical need in urban mobility: vehicles that are compact, efficient, and sustainable. By targeting smaller, more maneuverable designs, Also aims to reduce congestion and lower environmental impact in cities.
The massive investment will allow Also to accelerate development, scale manufacturing, and prepare for a 2026 product launch. With strong backing and a clear market opportunity, the company is positioned to redefine urban transportation.
California’s Innovation Pipeline is Wide Open
The range of Series A rounds in California this year shows how diverse the state’s innovation ecosystem has become
Startups in healthtech, enterprise software, AI infrastructure, and urban mobility are not just raising capital; they are moving quickly toward solving real problems with scalable solutions. Each funding milestone represents a step toward new products, expanded teams, and more competitive markets.
Investors are betting on ideas that combine advanced technology with strong execution. Whether it is designing AI-driven therapeutics, creating flexible ERP platforms, or building compact electric vehicles, these companies are pushing their industries toward new standards.
The fact that substantial funding spans from $12 million to $200 million signals that opportunity is not confined to a single niche or funding bracket.
California continues to be a proving ground for ambitious startups. The companies securing Series A rounds in 2025 are positioned to shape markets, influence technology adoption, and inspire the next wave of founders. For anyone tracking the future of tech, biotech, and fintech, these names are worth following closely.
FAQ
What does Series A funding mean for a startup?
Series A funding is the first significant round of venture capital investment a startup receives after seed funding. It allows companies to scale operations, expand their team, and develop their product or service beyond the proof-of-concept stage.
Why is California a hub for Series A startups?
California combines a strong venture capital network, top-tier universities, and a culture of innovation. This environment attracts investors and talent, making it a fertile ground for early-stage companies to grow and secure significant funding.
Which industries dominated California’s Series A rounds in 2025?
In 2025, the leading industries among California Series A startups were technology, biotechnology, and fintech. These sectors drew substantial investor interest due to their potential for rapid growth and long-term market impact.
What is the typical funding range for Series A rounds in 2025?
In 2025, California startups got a lot of money from Series A rounds. These rounds ranged from about $12 million for new healthtech companies to $200 million for companies that are growing quickly.
How do investors decide which startups to back in Series A rounds?
Investors assess factors such as market opportunity, product-market fit, revenue potential, leadership quality, and competitive differentiation. They look for companies with both strong fundamentals and the capacity to scale quickly.
Can smaller Series A rounds be as impactful as larger ones?
Yes. While larger rounds offer more capital for expansion, smaller Series A raises can still have a major impact, especially when companies operate in focused markets or have efficient scaling strategies.
